Published in Arthritis Rheum on July 01, 2009
Association of a Toll-like receptor 1 polymorphism with heightened Th1 inflammatory responses and antibiotic-refractory Lyme arthritis. Arthritis Rheum (2012) 1.79
Borrelia burgdorferi RST1 (OspC type A) genotype is associated with greater inflammation and more severe Lyme disease. Am J Pathol (2011) 1.21
A novel human autoantigen, endothelial cell growth factor, is a target of T and B cell responses in patients with Lyme disease. Arthritis Rheum (2013) 1.15
Treg cell numbers and function in patients with antibiotic-refractory or antibiotic-responsive Lyme arthritis. Arthritis Rheum (2010) 1.11
Relationship between immunity to Borrelia burgdorferi outer-surface protein A (OspA) and Lyme arthritis. Clin Infect Dis (2011) 1.03
Biodiversity of Borrelia burgdorferi strains in tissues of Lyme disease patients. PLoS One (2011) 1.00
The amber theory of Lyme arthritis: initial description and clinical implications. Clin Rheumatol (2012) 0.97
Ability to cause erythema migrans differs between Borrelia burgdorferi sensu lato isolates. Parasit Vectors (2013) 0.93
Review: unraveling Lyme disease. Arthritis Rheumatol (2014) 0.87
Antibodies to endothelial cell growth factor and obliterative microvascular lesions in the synovium of patients with antibiotic-refractory lyme arthritis. Arthritis Rheumatol (2014) 0.87
Natural killer cells and natural killer T cells in Lyme arthritis. Arthritis Res Ther (2013) 0.85
Diagnosis and treatment of Lyme arthritis. Infect Dis Clin North Am (2015) 0.84
Evolutionary Aspects of Emerging Lyme Disease in Canada. Appl Environ Microbiol (2015) 0.83
Detection of established virulence genes and plasmids to differentiate Borrelia burgdorferi strains. Infect Immun (2012) 0.79
Matrix metalloproteinase-10 is a target of T and B cell responses that correlate with synovial pathology in patients with antibiotic-refractory Lyme arthritis. J Autoimmun (2016) 0.79
Lyme borreliosis. Nat Rev Dis Prim (2016) 0.78
Toll-like receptor cascade and gene polymorphism in host-pathogen interaction in Lyme disease. J Inflamm Res (2016) 0.76
Tick-specific borrelial antigens appear to be upregulated in American but not European patients with Lyme arthritis, a late manifestation of Lyme borreliosis. J Infect Dis (2013) 0.76
Basic local alignment search tool. J Mol Biol (1990) 659.07
The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis (2006) 13.01
GenBank. Nucleic Acids Res (2006) 12.21
Case definitions for infectious conditions under public health surveillance. Centers for Disease Control and Prevention. MMWR Recomm Rep (1997) 10.41
Lyme disease. N Engl J Med (2001) 7.29
Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep (1995) 7.11
The clinical evolution of Lyme arthritis. Ann Intern Med (1987) 5.02
Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. N Engl J Med (1994) 4.07
Sequence typing reveals extensive strain diversity of the Lyme borreliosis agents Borrelia burgdorferi in North America and Borrelia afzelii in Europe. Microbiology (2004) 3.82
NEBcutter: A program to cleave DNA with restriction enzymes. Nucleic Acids Res (2003) 3.68
Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science (1998) 3.68
Genetic diversity of ospC in a local population of Borrelia burgdorferi sensu stricto. Genetics (1999) 3.46
Four clones of Borrelia burgdorferi sensu stricto cause invasive infection in humans. Infect Immun (1999) 3.41
Association of specific subtypes of Borrelia burgdorferi with hematogenous dissemination in early Lyme disease. J Infect Dis (1999) 2.64
Genetic diversity of Borrelia burgdorferi in lyme disease patients as determined by culture versus direct PCR with clinical specimens. J Clin Microbiol (1999) 2.35
Treatment of Lyme arthritis. Arthritis Rheum (1994) 2.27
Borrelia burgdorferi genotype predicts the capacity for hematogenous dissemination during early Lyme disease. J Infect Dis (2008) 2.26
Successful parenteral penicillin therapy of established Lyme arthritis. N Engl J Med (1985) 2.23
Treatment of late Lyme borreliosis--randomised comparison of ceftriaxone and penicillin. Lancet (1988) 2.11
Association of antibiotic treatment-resistant Lyme arthritis with T cell responses to dominant epitopes of outer surface protein A of Borrelia burgdorferi. Arthritis Rheum (1999) 2.01
Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheum (2006) 1.98
Disease severity in a murine model of lyme borreliosis is associated with the genotype of the infecting Borrelia burgdorferi sensu stricto strain. J Infect Dis (2002) 1.97
Impact of genotypic variation of Borrelia burgdorferi sensu stricto on kinetics of dissemination and severity of disease in C3H/HeJ mice. Infect Immun (2001) 1.93
Borrelia burgdorferi in joint fluid in chronic Lyme arthritis. Ann Intern Med (1986) 1.86
Cultivation of Borrelia burgdorferi from joint fluid three months after treatment of facial palsy due to Lyme borreliosis. J Infect Dis (1988) 1.81
Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med (2006) 1.67
Borrelia burgdorferi genetic markers and disseminated disease in patients with early Lyme disease. J Clin Microbiol (2006) 1.66
Arthritis severity and spirochete burden are determined by serotype in the Borrelia turicatae-mouse model of Lyme disease. Infect Immun (1997) 1.51
Borrelia burgdorferi ospC heterogeneity among human and murine isolates from a defined region of northern Maryland and southern Pennsylvania: lack of correlation with invasive and noninvasive genotypes. J Clin Microbiol (2005) 1.46
Wide distribution of a high-virulence Borrelia burgdorferi clone in Europe and North America. Emerg Infect Dis (2008) 1.43
Immunologic and genetic analyses of VmpA of a neurotropic strain of Borrelia turicatae. Infect Immun (1997) 1.42
High levels of inflammatory chemokines and cytokines in joint fluid and synovial tissue throughout the course of antibiotic-refractory lyme arthritis. Arthritis Rheum (2007) 1.37
Genetic diversity among Borrelia strains determined by single-strand conformation polymorphism analysis of the ospC gene and its association with invasiveness. J Clin Microbiol (2003) 1.31
Searching for borrelial T cell epitopes associated with antibiotic-refractory Lyme arthritis. Mol Immunol (2008) 1.30
Lack of Borrelia burgdorferi DNA in synovial samples from patients with antibiotic treatment-resistant Lyme arthritis. Arthritis Rheum (1999) 1.27
Characterization of VspB of Borrelia turicatae, a major outer membrane protein expressed in blood and tissues of mice. Infect Immun (1999) 1.25
Borrelia burgdorferi sensu stricto is clonal in patients with early Lyme borreliosis. Appl Environ Microbiol (2008) 1.16
Borrelia burgdorferi sensu stricto invasiveness is correlated with OspC-plasminogen affinity. Microbes Infect (2006) 1.12
Comparative transcriptional profiling of Borrelia burgdorferi clinical isolates differing in capacities for hematogenous dissemination. Infect Immun (2005) 1.11
Isogenic serotypes of Borrelia turicatae show different localization in the brain and skin of mice. Infect Immun (2001) 1.11
Comparison of disseminated and nondisseminated strains of Borrelia burgdorferi sensu stricto in mice naturally infected by tick bite. Infect Immun (2004) 0.97
Molecular characterization of the OspA(161-175) T cell epitope associated with treatment-resistant Lyme arthritis: differences among the three pathogenic species of Borrelia burgdorferi sensu lato. J Autoimmun (2004) 0.90
The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis (2006) 13.01
A critical appraisal of "chronic Lyme disease". N Engl J Med (2007) 7.84
Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann Intern Med (2002) 3.41
Elevated levels of IL-23 in a subset of patients with post-lyme disease symptoms following erythema migrans. Clin Infect Dis (2013) 3.36
Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates. J Infect Dis (2003) 3.18
Antiscience and ethical concerns associated with advocacy of Lyme disease. Lancet Infect Dis (2011) 2.88
Borrelia burgdorferi NapA-driven Th17 cell inflammation in lyme arthritis. Arthritis Rheum (2008) 2.45
Antibody responses to Borrelia burgdorferi in patients with antibiotic-refractory, antibiotic-responsive, or non-antibiotic-treated Lyme arthritis. Arthritis Rheum (2007) 2.20
A genome-wide proteome array reveals a limited set of immunogens in natural infections of humans and white-footed mice with Borrelia burgdorferi. Infect Immun (2008) 2.15
Case records of the Massachusetts General Hospital. Case 11-2007. A 59-year-old man with neck pain, weakness in the arms, and cranial-nerve palsies. N Engl J Med (2007) 2.11
Performance of United States serologic assays in the diagnosis of Lyme borreliosis acquired in Europe. Clin Infect Dis (2013) 1.82
Association of a Toll-like receptor 1 polymorphism with heightened Th1 inflammatory responses and antibiotic-refractory Lyme arthritis. Arthritis Rheum (2012) 1.79
Reinfection versus relapse in Lyme disease. N Engl J Med (2012) 1.70
Borrelia burgdorferi genetic markers and disseminated disease in patients with early Lyme disease. J Clin Microbiol (2006) 1.66
Two-tiered antibody testing for Lyme disease with use of 2 enzyme immunoassays, a whole-cell sonicate enzyme immunoassay followed by a VlsE C6 peptide enzyme immunoassay. Clin Infect Dis (2011) 1.49
Borrelia burgdorferi stimulation of chemokine secretion by cells of monocyte lineage in patients with Lyme arthritis. Arthritis Res Ther (2010) 1.46
Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease. Diagn Microbiol Infect Dis (2012) 1.45
The presenting manifestations of Lyme disease and the outcomes of treatment. N Engl J Med (2003) 1.45
Burden and viability of Borrelia burgdorferi in skin and joints of patients with erythema migrans or lyme arthritis. Arthritis Rheum (2011) 1.44
Duration of antibiotic therapy for Lyme disease. Ann Intern Med (2003) 1.39
High levels of inflammatory chemokines and cytokines in joint fluid and synovial tissue throughout the course of antibiotic-refractory lyme arthritis. Arthritis Rheum (2007) 1.37
Searching for borrelial T cell epitopes associated with antibiotic-refractory Lyme arthritis. Mol Immunol (2008) 1.30
Borrelia burgdorferi RST1 (OspC type A) genotype is associated with greater inflammation and more severe Lyme disease. Am J Pathol (2011) 1.21
Human homologues of a Borrelia T cell epitope associated with antibiotic-refractory Lyme arthritis. Mol Immunol (2007) 1.20
2-tiered antibody testing for early and late Lyme disease using only an immunoglobulin G blot with the addition of a VlsE band as the second-tier test. Clin Infect Dis (2010) 1.15
A novel human autoantigen, endothelial cell growth factor, is a target of T and B cell responses in patients with Lyme disease. Arthritis Rheum (2013) 1.15
Treg cell numbers and function in patients with antibiotic-refractory or antibiotic-responsive Lyme arthritis. Arthritis Rheum (2010) 1.11
Chemokine signatures in the skin disorders of Lyme borreliosis in Europe: predominance of CXCL9 and CXCL10 in erythema migrans and acrodermatitis and CXCL13 in lymphocytoma. Infect Immun (2007) 1.11
Persistence of the antibody response to the VlsE sixth invariant region (IR6) peptide of Borrelia burgdorferi after successful antibiotic treatment of Lyme disease. J Infect Dis (2003) 1.09
Higher mRNA levels of chemokines and cytokines associated with macrophage activation in erythema migrans skin lesions in patients from the United States than in patients from Austria with Lyme borreliosis. Clin Infect Dis (2008) 1.06
The VlsE (IR6) peptide ELISA in the serodiagnosis of lyme facial paralysis. Otol Neurotol (2004) 1.05
Induction of host matrix metalloproteinases by Borrelia burgdorferi differs in human and murine lyme arthritis. Infect Immun (2005) 1.04
Relationship between immunity to Borrelia burgdorferi outer-surface protein A (OspA) and Lyme arthritis. Clin Infect Dis (2011) 1.03
Inflammatory cytokine production predominates in early Lyme disease in patients with erythema migrans. Infect Immun (2003) 1.02
Borrelia burgdorferi stimulates macrophages to secrete higher levels of cytokines and chemokines than Borrelia afzelii or Borrelia garinii. J Infect Dis (2009) 1.01
Clinical correlations with Porphyromonas gingivalis antibody responses in patients with early rheumatoid arthritis. Arthritis Res Ther (2013) 0.99
Peptides presented by HLA-DR molecules in synovia of patients with rheumatoid arthritis or antibiotic-refractory Lyme arthritis. Mol Cell Proteomics (2010) 0.98
Multiplex immunoassay for Lyme disease using VlsE1-IgG and pepC10-IgM antibodies: improving test performance through bioinformatics. Clin Vaccine Immunol (2011) 0.97
Dysregulation of CD4+CD25(high) T cells in the synovial fluid of patients with antibiotic-refractory Lyme arthritis. Arthritis Rheum (2013) 0.93
Human Lyme arthritis and the immunoglobulin G antibody response to the 37-kilodalton arthritis-related protein of Borrelia burgdorferi. Infect Immun (2005) 0.93
Molecular characterization of the OspA(161-175) T cell epitope associated with treatment-resistant Lyme arthritis: differences among the three pathogenic species of Borrelia burgdorferi sensu lato. J Autoimmun (2004) 0.90
Strong IgG antibody responses to Borrelia burgdorferi glycolipids in patients with Lyme arthritis, a late manifestation of the infection. Clin Immunol (2009) 0.89
Role of aggrecanase 1 in Lyme arthritis. Arthritis Rheum (2006) 0.88
Antibodies to endothelial cell growth factor and obliterative microvascular lesions in the synovium of patients with antibiotic-refractory lyme arthritis. Arthritis Rheumatol (2014) 0.87
In situ diversification of the antibody repertoire in chronic Lyme arthritis synovium. J Immunol (2005) 0.87
Natural killer cells and natural killer T cells in Lyme arthritis. Arthritis Res Ther (2013) 0.85
Anti-tumor necrosis factor-alpha activation of Borrelia burgdorferi spirochetes in antibiotic-treated murine Lyme borreliosis: an unproven conclusion. J Infect Dis (2007) 0.78
Arthritogenicity of Borrelia burgdorferi and Borrelia garinii: comparison of infection in mice. Am J Trop Med Hyg (2009) 0.78
Case records of the Massachusetts General Hospital. Case 14-2005. A 38-year-old man with fever and blurred vision. N Engl J Med (2005) 0.78
Differences in Genotype, Clinical Features, and Inflammatory Potential of Borrelia burgdorferi sensu stricto Strains from Europe and the United States. Emerg Infect Dis (2016) 0.77
Cerebellar ataxia as the presenting manifestation of Lyme disease. Pediatr Infect Dis J (2002) 0.76
Tick-specific borrelial antigens appear to be upregulated in American but not European patients with Lyme arthritis, a late manifestation of Lyme borreliosis. J Infect Dis (2013) 0.76
Reinfection versus relapse in Lyme disease. N Engl J Med (2013) 0.75
Reply to letter by Volkman commenting on the possible onset of seronegative disease in Lyme arthritis. Arthritis Rheum (2009) 0.75
Reply to Parvu and Parvu. Clin Infect Dis (2014) 0.75
Role of adrenomedullin in Lyme disease. Infect Immun (2010) 0.75
Correction: Lyme borreliosis. Nat Rev Dis Prim (2017) 0.75